Search

everythinglearnresearchcommunity

for

Search:↓

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Canakinumab's effect on COVID-19 outcomes is unclear.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

Mogamulizumab can cause hair loss and skin rashes.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Adalimumab can cause complete hair loss in rare cases.

Etanercept effectively treated a severe skin condition when other treatments failed.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Ustekinumab treatment may reveal a genetic tendency for steatocystoma multiplex in psoriasis patients.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

Ustekinumab effectively treated psoriasis and ulcerative colitis in a teen after infliximab caused complications.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Bimekizumab can improve scarring alopecia in severe psoriasis.

Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.

Dupilumab effectively treated severe alopecia areata in a child.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.